ArticleDrug delivery and translational research2026
Next-generation GTR/GBR membranes: synergistic effects of nano-hydroxyapatite and vitamin D
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To develop a multifunctional membrane for guided tissue/bone regeneration (GTR/GBR), this study investigated the effect of incorporating nano‑hydroxyapatite (nHA) and vitamin D3 (VitD3) into electrospun polylactic acid (PLA) on scaffold properties and bone regeneration performance. Electrospun PLA/nHA-VitD3 membranes were fabricated and compared with neat PLA and a commercial membrane. Fiber morphology and porosity, water contact angle, tensile properties, and VitD3 release over 28 days were evaluated. In vitro performance was assessed using MG‑63 osteoblast viability and mineralization potential, while in vivo efficacy was examined in a rabbit calvarial defect model after 8 weeks. The PLA/nHA-VitD3 membranes exhibited reduced fiber diameter ( ~ 745 vs ~1039 nm) and higher porosity ( ~ 90% vs ~81%) compared with PLA, along with improved surface wettability (contact angle from 152° to 137%). Mechanical performance was enhanced, with tensile strength increasing from 0.10 ± 0.02 to 0.21 ± 0.05 MPa, Young's modulus from 1.48 ± 0.3 to 15.1 ± 3.6 MPa, and elongation at break from 21% to 46%. VitD3 release from the composite membrane was sustained over 28 days ( ~ 85% cumulative release) without an initial burst. In vitro results showed increased MG‑63 cell viability ( ~ 1.8‑fold vs PLA at day 5) together with evidence of mineralization potential. In addition, osteogenic gene expression analysis showed upregulation of COL1A and RUNX2 in cells cultured on the PLA/nHA-VitD3 membrane, indicating enhanced early osteogenic activity. In the rabbit calvarial model, PLA/nHA-VitD3 membranes promoted ~82% new bone formation at 8 weeks, compared with ~54% for PLA and ~65% for the commercial membrane, with complete defect bridging and minimal inflammatory response. Overall, the incorporation of nHA and VitD3 improved the structural, mechanical, and biological performance of electrospun PLA membranes and contributed to enhanced bone regeneration, supporting their potential use as GBR/GTR barrier membranes.
Indexed as
Identifiers
42440251What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.